Subgroup C

Subgroup C: Cell Biology in Cancer Immunity

Saturday, December 8, 8:30 am-12:30 pm
Room: 31B

Organizers: Xiaolei Su, Yale University; and Enfu Hui, University of California, San Diego

Cancer immunotherapy aims to activate or release the inhibition of immune cells for the sake of killing tumors. A variety of signaling molecules or immune effectors, including cell surface receptors, antibodies, and cytokines, have been targeted or engineered for eliminating cancer cells. Despite the clinical success in various immunotherapies, including checkpoint blockade and CAR-T, the cellular mechanism underlying how immune cells respond in those therapies remains unclear. This session will focus on recent progress in understanding and manipulating signaling events, transcriptional program, and reorganization of cellular structures that mediate immune cells’ responses to cancer antigens. It will not only advance our knowledge in understanding the molecular mechanism underlying cancer immunity but also provide insights in designing new strategies for cancer therapy.

Presentations:

8:30 am          Introduction. Xiaolei Su, Yale University, and Enfu Hui, University of California, San Diego

8:35 am          Phase Separation in Chimeric Antigen Receptor (CAR) Signaling. Xiaolei Su, Yale University

8:55 am          Engineering Next-Generation T Cells for Cancer Immunotherapy. Yvonne Chen, University of California, Los Angeles

9:15 am          Engineering the Next-Generation of Immune Cell Therapies for Cancer. Kole Roybal, University of California, San Francisco

9:35 am          TCR Catch Bonds with Antigenic pMHC Activate T Cell Signaling and Its Implication for Effective Immunotherapy. Wei Chen, Zhejiang University

9:55 am          Mechanopotentiation at the Cytotoxic Immunological Synapse. Morgan Huse, Memorial Sloan-Kettering Cancer Center

10:15 am        Break

10:30 am        Self-Cancellation of the PD-L1/PD-1 Pathway. Enfu Hui, University of California, San Diego

10:50 am        Understanding T Cell Inhibition and Costimulation to Improve Cancer Immunotherapy. Alice Kamphorst, Icahn School of Medicine at Mount Sinai

11:10 am        Integration of Signals for Activation and Inhibition of NK Cells. Eric Long, National Institute of Allergy and Infectious Diseases

11:30 am        Biomimetic Nanoparticles for Anticancer Vaccination. Liangfang Zhang, University of California, San Diego

11:50 am        Engineering Phagocytic Receptors to Dissect Engulfment Signaling and Target Cancer. Adam Williamson, University of California, San Francisco

12:10 pm        Using Microscopy to Inform the Engineering of Therapeutic Antibodies. Sally Ward, University of Southampton/Texas A&M University Health Science Center

 

Click here to return to full list of Special Interest Subgroups.